Some healthcare workers, first in line to receive the jab, told FIT that lack of transparency around the vaccines is giving rise to hesitancy among them.
“Both vaccines are publicly funded and both have issues with lack of data. For Covaxin, phase 3 trials are still ongoing and no raw data is available. For both Covishield and Covaxin, information around adverse events remains opaque. There is concern among doctor groups regarding the roll-out, specially around adverse events involving neurological symptoms,” says Dr Sumit Ray, Critical Care specialist at Delhi’s Holy Family Hospital.
Malini Aisola, co-convenor of the All India Drug Action Network, tweeted about lack data on the 4-week dosing schedule that has been approved by the government for Covishield. The Indian bridge trials for the Oxford AstraZeneca vaccine, being manufactured in India by Serum Institute, are still ongoing.
Speaking with FIT, Dr Gangandeep Kang, virologist from CMC Vellore, had said, “The question is at what…
